Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > August 30, 2024
Daily News
August 30, 2024
- Majority of PNH Patients Expected to Switch to Novartis’ Fabhalta: Expert
August 30, 2024
- LDP Study Group Mulls Seeking More Budget for Immunoglobulins in FY2025
August 30, 2024
- AstraZeneca Japan Launches Research on Lung Cancer Survival Rate Using National Registry
August 30, 2024
- FY2025 Budget Request Earmarks Funding to Systematize Collection of Drug Supply Info
August 30, 2024
- MHLW Seeks 19.8 Billion Yen for Launch of Pandemic Agency JIHS in April
August 30, 2024
- JCR’s JR-441 Primed for Japan Clinical Trial in MPS IIIA
August 30, 2024
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…